Product Information
Registration Status: ActiveSIN11199P
RELENZA ROTADISK 5mg/DOSE is approved to be sold in Singapore with effective from 1999-10-21. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN11199P.
This product contains Zanamivir 5mg/dose in the form of POWDER, METERED. It is approved for RESPIRATORY (INHALATION) use.
This product is manufactured by GLAXO WELLCOME PRODUCTION in FRANCE, andGlaxoSmithKline Australia Pty Ltd in AUSTRALIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A guanido-neuraminic acid that is used to inhibit neuraminidase. [PubChem]
Indication
For the prevention and treatment of influenza A and B.
Mechanism of Action
The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
Pharmacokinetics
- Absorption
- Absolute bioavailability is very low following oral administration (2%). Following oral inhalation, bioavailability is 4% to 17%.
- Distribution
- Metabolism
- Not metabolized
- Elimination
Clearance
* 2.5 - 10.9 L/h [Following oral inhalation 10 mg] * 5.3 L/h [Normal renal function receiving IV single dose of 4 mg or 2 mg] * 2.7 L/h [Patients with mild and moderate renal impairement receiving IV single dose of 4 mg or 2 mg] * 0.8 L/h [Patients with severe renal impairement receiving IV single dose of 4 mg or 2 mg]
Active Ingredient/Synonyms
(2R,3R,4S)-3-(acetylamino)-4-Carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid | 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid | 4-Guanidino-neu5ac2en | 5-(acetylamino)-2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid | 5-acetamido-2,6-Anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid | GANA | GNA | Modified sialic acid | Zanamavir | ZANAMIVIR | ZMR | Zanamivir |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.